Evidence map›Paper›PMID 24224649›Full record

Trial reportBritish journal of haematology2014

A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia.

Adlette Inati, Mario Kahale, Susan P Perrine, David H K Chui, Ali T Taher, Suzanne Koussa, Therese Abi Nasr, Hussein A Abbas, Richard G Ghalie

Abstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Thalassaemia.Nature reviews. Disease primers · 2026
    Review
  2. Evolution of hemoglobin loci and their regulatory elements.Blood cells, molecules & diseases · 2018
    Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adlette InatiLebanese American University, Beirut, Lebanon; Rafik Hariri University Hospital, Beirut, Lebanon.
Mario Kahale
Susan P Perrine
David H K Chui
Ali T Taher
Suzanne Koussa
Therese Abi Nasr
Hussein A Abbas
Richard G Ghalie

Funding

NOVEL GLOBIN GENE MODULATORSR01DK052962 · NIDDK · BOSTON UNIVERSITY MEDICAL CAMPUS · PI PERRINE, SUSAN PARK · 1998 to 2016
$4.2M
Next Generation Therapeutics for HemoglobinopathiesR41HL108516 · NHLBI · PHOENICIA BIOSCIENCES, INC. · PI PERRINE, SUSAN PARK · 2012 to 2012
$491k
in vivo Studies of Clinical Stage Globin ModulatorsR41HL110727 · NHLBI · PHOENICIA BIOSCIENCES, INC. · PI PERRINE, SUSAN PARK · 2011 to 2011
$304k
Oral Therapeutic for Beta-ThalassemiaR42DK064535 · NIDDK · GENE REGULATION LABORATORIES, INC. · PI PERRINE, SUSAN PARK · 2005 to 2006
$287k
NHLBI NIH HHS R41 HL108516NHLBI NIH HHS R41 HL110727NIDDK NIH HHS R01 DK052962NIDDK NIH HHS R01-DK-52962NIDDK NIH HHS R42 DK064535
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultbeta-ThalassemiaButyratesFemaleFetal HemoglobinHumansMaleMiddle AgedYoung Adult2,2-dimethylbutyric acidButyratesFetal Hemoglobinanaemiafetal haemoglobingene expressionhaemoglobinopathiesβ-thalassaemia

Identifiers

PMID24224649
PMCPMC3904791

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.